BOCA RATON, Fla., Jan. 25, 2018 /PRNewswire/ -- Sensus Healthcare, Inc. (Nasdaq: SRTS), a medical device company specializing in the non-invasive treatment of non-melanoma skin cancers and keloids with superficial radiation therapy (SRT), announces that management will hold a conference call on Thursday, February 1, 2018 at 4:30 p.m. ET to discuss the financial results for the fourth quarter and year ended December 31, 2017. In addition, management will provide a business update and a discussion on recent and upcoming milestones.
To access the conference call, the dial-in numbers are 855-940-9473 (U.S. Toll Free), 412-317-5220 (International), and 855-669-9657 (Canada Toll Free). Please direct the operator to be connected to the Sensus Healthcare call.
Following the conclusion of the conference call, a replay will be available through February 8, 2018 and can be accessed by dialing 877-344-7529 (U.S. Toll Free), 412-317-0088 (International), and 855-669-9658 (Canada Toll Free). All listeners should provide the following replay access code: 10116554. The call will also be archived on the Company's website for a period of time at www.sensushealthcare.com.
About Sensus Healthcare
Sensus Healthcare, Inc. is a medical device company that is committed to providing non-invasive and cost-effective treatment for non-melanoma skin cancers and keloids. Sensus uses a proprietary low energy X-ray technology known as superficial radiation therapy (SRT), which is a result of over a decade of dedicated research and development. Sensus has successfully incorporated SRT therapy into its portfolio of treatment devices, the SRT-100™ and SRT-100 Vision™. To date, SRT technology has been used to effectively and safely treat oncological and non-oncological skin conditions in thousands of patients. For more information, visit http://www.sensushealthcare.com.
LHA Investor Relations
Kim Sutton Golodetz
SOURCE Sensus Healthcare